Replies to post #186984 on Biotech Values

[masterlongevity]

It's temporary. It's very rare for 2 groundbreaking therapies , with equivalent efficacy, to get approved for a large market in such short order. When there is a clear efficacy or safety advantage, this won't happen
$gild $enta